Skip to Main Content

Nimer Lab

Transcriptional & Epigenetic Regulation of Normal and Malignant Hematopoiesis

Contact Us

Investigator / Contact Person Stephen Nimer


2019Page 1
  • TAF1 plays a critical role in AML1-ETO driven leukemogenesis. View in PubMed
2018Page 1
  • Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML. View in PubMed
  • PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes. View in PubMed
2017Page 1
  • Histone-binding of DPF2 mediates its repressive role in myeloid differentiation. View In PubMed
  • Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner. View In PubMed
2016Page 1
  • Loss of p300 accelerates MDS-associated leukemogenesis. View In PubMed
  • Beyond transcription factors: how oncogenic signaling reshapes the epigenetic landscape. View In PubMed
  • Arginine methyltransferases in normal and malignant hematopoiesis. View In PubMed
  • Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms. View In PubMed
  • Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin. View In PubMed
  • Mutational Landscape and Antiproliferative Functions of ELF Transcription Factors in Human Cancer. View In PubMed
2015Page 1
  • Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles. View In PubMed
  • PARP inhibitors: a treatment option for AML? View In PubMed
  • The Role of Histone Acetyltransferases in Normal and Malignant Hematopoiesis. View In PubMed
  • Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. View In PubMed
  • Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. View In PubMed
2014Page 1
  • Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. View In PubMed
2013Page 1
  • Mutations in the nucleolar phosphoprotein, nucleophosmin, promote the expression of the oncogenic transcription factor MEF/ELF4 in leukemia cells and potentiates transformation. View In PubMed
  • Necdin, a p53 target gene, in stem cells View In PMC
2012Page 1
  • Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. View In PubMed
  • Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. View In PubMed
  • Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells. View In PubMed
  • The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. View In PubMed
2011Page 1
  • The p53 tumor suppressor protein regulates hematopoietic stem cell fate. View In PubMed
  • Nuclear JAK2. View In PubMed
  • The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. View In PubMed
  • JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. View In PubMed
  • The mef/elf4 transcription factor fine tunes the DNA damage response. View In PubMed
2010Page 1
  • Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: possible role in 20q- polycythemia vera. View In PubMed